Summary
Definition
History and exam
Key diagnostic factors
- fatigue
Other diagnostic factors
- altered mental status
- headache
- nausea and/or vomiting
- gait abnormality
- ataxia
- weakness
- seizures
- visual disturbances
- speech deficit
- aphasia/dysphasia
- sensory deficit
- motor weakness
- visual change
- cranial nerve palsy
- papilledema
- personality change/emotional lability
Risk factors
- white ancestry
- male sex
- neurofibromatosis type 1
- tuberous sclerosis complex
- Li-Fraumeni syndrome
- Turcot syndrome
- ionizing radiation
Diagnostic tests
1st tests to order
- MRI head
- ophthalmologic evaluation; visual field testing
- CT head
- brain MR spectroscopy
- brain perfusion MRI
- histopathology
- molecular analyses
Tests to consider
- pituitary hormones tests
- diffusion tensor imaging (DTI)
Emerging tests
- 2-hydroxyglutarate-targeted magnetic resonance spectroscopy
- amino acid PET
- cerebrospinal fluid liquid biopsy
Treatment algorithm
circumscribed glioma: pediatric low-grade gliomas including pilocytic astrocytoma
circumscribed glioma: subependymal giant cell astrocytoma (grade 1)
circumscribed glioma: pleomorphic xanthoastrocytoma
diffuse infiltrating glioma: grade 2 and accessible
diffuse infiltrating glioma: grade 2 and inaccessible
high-grade diffuse infiltrating glioma
diffuse midline glioma, H3 K27M-altered, grade 4
recurrent circumscribed glioma
progressive diffuse infiltrating glioma
Contributors
Authors
Douglas E. Ney, MD
Director of Medical Neuro-Oncology
Cottage Health Neurosciences
Santa Barbara, CA
Disclosures
DEN declares that he has no competing interests.
Acknowledgements
Dr Douglas E. Ney would like to gratefully acknowledge Dr L. Nicolas Gonzalez Castro, Dr Timothy C. Ryken, Dr Linton T. Evans, Dr Manmeet S. Ahluwalia, Dr Susan Chang, and Dr Karine Michaud, previous contributors to this topic.
Disclosures
LNGC has received consulting fees from Elsevier, Oakstone Publishing, and Teladoc. LNGC has received research funding from Merck & Co. (to Dana-Farber Cancer Institute). LNGC is an author of a number of references cited in this topic. TCR is an author of a number of references cited in this topic. MSA has acted as a consultant for Elekta, Incyte, AstraZeneca, Novocure, Caris Life Sciences, Bristol-Myers Squibb, Monteris Medical, AbbVie, MRI Solutions, Elsevier, and Prime oncology. MSA has received clinical trial investigations grants from Tracon, Bristol-Myers Squibb, AstraZeneca, Novartis, and Novocure. SC has received research support from Agios, Novartis, Quest, Roche, and Schering Plough. KM and LTE declare that they have no competing interests.
Peer reviewers
David A. Reardon, MD
Associate Professor
The Preston Robert Tisch Brain Tumor Center
Duke University Medical Center
Durham, NC
Disclosures
DAR declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-51.Full text Abstract
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].Full text
European Association of Neuro-Oncology. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. 2021 [internet publication].Full text
Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2025 Nov 1;27(11):2751-88.Full text Abstract
American Society of Clinical Oncology; Society for Neuro-Oncology. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. 2022 [internet publication].Full text
American Association of Neurological Surgeons; Congress of Neurological Surgeons. Updated AANS/CNS guidelines for progressive glioblastoma patients. Jun 2022 [internet publication].Full text
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Differentials
- Brain metastasis
- Brain abscess
- Multiple sclerosis
More DifferentialsGuidelines
- NCCN clinical practice guidelines in oncology: central nervous system cancers
- Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline
More GuidelinesLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer